SALT
LAKE CITY, Aug. 2, 2022 /PRNewswire/ -- Recursion
(NASDAQ: RXRX), the clinical-stage biotechnology company
industrializing drug discovery by decoding biology, today announced
its participation in the following investor conference:
- KeyBanc Technology Leadership Forum — August 8 through August 9, 2022
About Recursion
Recursion is the clinical-stage biotechnology company
industrializing drug discovery by decoding biology. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world's largest
proprietary biological and chemical datasets. Recursion leverages
sophisticated machine-learning algorithms to distill from its
dataset a collection of trillions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating one of the most powerful supercomputers in the world,
Recursion is uniting technology, biology and chemistry to advance
the future of medicine.
Recursion is headquartered in Salt
Lake City, where it is a founding member of BioHive, the
Utah life sciences industry
collective. Recursion also has offices in Toronto Montréal and
the San Francisco Bay Area. Learn
more at www.Recursion.com, or connect on Twitter
and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking
Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding early and late stage discovery,
preclinical, and clinical programs; licenses and collaborations;
prospective products and their potential future indications and
market opportunities; Recursion OS and other technologies; business
and financial plans and performance; and all other statements that
are not historical facts. Forward-looking statements may or may not
include identifying words such as "plan," "will," "expect,"
"anticipate," "intend," "believe," "potential," "continue," and
similar terms. These statements are subject to known or unknown
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements,
including but not limited to: challenges inherent in pharmaceutical
research and development, including the timing and results of
preclinical and clinical programs, where the risk of failure is
high and failure can occur at any stage prior to or after
regulatory approval due to lack of sufficient efficacy, safety
considerations, or other factors; our ability to leverage and
enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; the impact of the COVID-19 pandemic and force majeure
events; our ability to obtain, maintain, and enforce intellectual
property protections; cyberattacks or other disruptions to our
technology systems; our ability to attract, motivate, and retain
key employees and manage our growth; inflation and other
macroeconomic issues; and other risks and uncertainties such as
those described under the heading "Risk Factors" in our filings
with the U.S. Securities and Exchange Commission, including our
most recent Quarterly Report on Form 10-Q and our Annual Report on
Form 10-K. All forward-looking statements are based on management's
current estimates, projections, and assumptions, and Recursion
undertakes no obligation to correct or update any such statements,
whether as a result of new information, future developments, or
otherwise, except to the extent required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recursion-to-participate-in-upcoming-investor-conference-301597705.html
SOURCE Recursion